A carregar...
PCSK9 Inhibitors: A Technology Worth Paying For?
Food and Drug Administration in the United States has approved the (PCSK9) inhibitors alirocumab and evolocumab as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (FH) or clinical atherosclerotic cardiovascular disease requiring ad...
Na minha lista:
| Publicado no: | Pharmacoeconomics |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4816976/ https://ncbi.nlm.nih.gov/pubmed/26689785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0355-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|